Table 3. Availability and reimbursement of testing for EGFR mutation, ALK rearrangement, ROS1 mutation, BRAF mutation, and PD‐L1 overexpression and of liquid biopsies in countries of central and southeastern Europe.

Abbreviations: EGFR, epidermal growth factor receptor; NA, not applicable; NSCLC, non‐small cell lung cancer; PD‐L1, programmed death‐ligand 1.